EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

Stefan Zwirner, Anan A Abu Rmilah, Sabrina Klotz, Bent Pfaffenroth, Philip Kloevekorn, Athina A Moschopoulou, Svenja Schuette, Mathias Haag, Roland Selig, Kewei Li, Wei Zhou, Erek Nelson und 31 weitere

Cell · 2024-03 · 187 (7) · 1666-1684.e26

DOI: 10.1016/j.cell.2024.02.023 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cell, 2024-03. Verfasst von Stefan Zwirner und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tübingen, Tübingen 72076, Germany; HepaRegeniX GmbH, Tübi…. Hauptthemen laut MEDLINE: Liver Failure, MAP Kinase Kinase 4, Enzyme Inhibitors. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Deutsche Forschungsgemeinschaft, Universiteit Utrecht.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diminished hepatocyte regeneration is a key feature of acute and chronic liver diseases and after extended liver resections, resulting in the inability to maintain or restore a sufficient functional liver mass. Therapies to restore hepatocyte regeneration are lacking, making liver transplantation the only curative option for end-stage liver disease. Here, we report on the structure-based development and characterization (nuclear magnetic resonance [NMR] spectroscopy) of first-in-class small molecule inhibitors of the dual-specificity kinase MKK4 (MKK4i). MKK4i increased liver regeneration upon hepatectomy in murine and porcine models, allowed for survival of pigs in a lethal 85% hepatectomy model, and showed antisteatotic and antifibrotic effects in liver disease mouse models. A first-in-human phase I trial (European Union Drug Regulating Authorities Clinical Trials [EudraCT] 2021-000193-28) with the clinical candidate HRX215 was conducted and revealed excellent safety and pharmacokinetics. Clinical trials to probe HRX215 for prevention/treatment of liver failure after extensive oncological liver resections or after transplantation of small grafts are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver FailureMAP Kinase Kinase 4Enzyme InhibitorsAnimalsHumansMiceHepatectomyHepatocytesLiverLiver DiseasesLiver RegenerationSwine

Stichwörter der Autor:innen

MKK4drug discovery and developmentfirst-in-human phase I trialliverliver failureliver regenerationpartial hepatectomy

Substanzen

MAP Kinase Kinase 4Enzyme Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tübingen, Tübingen 72076, Germany; HepaRegeniX GmbH, Tübingen 72072, Germany.
  • William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tübingen, Tübingen 72076, Germany.
  • Department of Pharmaceutical Chemistry, University of Tübingen, Tübingen 72076, Germany.
  • Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart 70376, Germany.
  • HepaRegeniX GmbH, Tübingen 72072, Germany; Department of Pharmaceutical Chemistry, University of Tübingen, Tübingen 72076, Germany.

Förderung

  • NIDDK NIH HHS
  • Deutsche Forschungsgemeinschaft
  • Universiteit Utrecht
  • Robert Bosch
  • Gilead Sciences
  • German Cancer Consortium
  • Robert-Bosch Foundation GmbH

Zitieren

APA

Zwirner, S., Abu Rmilah, A. A., Klotz, S., Pfaffenroth, B., Kloevekorn, P., Moschopoulou, A. A., Schuette, S., Haag, M., Selig, R., Li, K., Zhou, W., Nelson, E., Poso, A., Chen, H., Amiot, B., Jia, Y., Minshew, A., Michalak, G., Cui, W., …, & Zender, L. (2024). First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187(7), 1666-1684.e26. https://doi.org/10.1016/j.cell.2024.02.023

Vancouver

Zwirner S, Abu Rmilah AA, Klotz S, Pfaffenroth B, Kloevekorn P, Moschopoulou AA, et al. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell. 2024;187(7):1666-1684.e26. doi:10.1016/j.cell.2024.02.023

BibTeX
@article{Zwirner2024,
  author = {Zwirner, Stefan and Abu Rmilah, Anan A and Klotz, Sabrina and Pfaffenroth, Bent and Kloevekorn, Philip and Moschopoulou, Athina A and Schuette, Svenja and Haag, Mathias and Selig, Roland and Li, Kewei and Zhou, Wei and Nelson, Erek and Poso, Antti and Chen, Harvey and Amiot, Bruce and Jia, Yao and Minshew, Anna and Michalak, Gregory and Cui, Wei and Rist, Elke and Longerich, Thomas and Jung, Birgit and Felgendreff, Philipp and Trompak, Omelyan and Premsrirut, Prem K and Gries, Katharina and Muerdter, Thomas E and Heinkele, Georg and Wuestefeld, Torsten and Shapiro, David and Weissbach, Markus and Koenigsrainer, Alfred and Sipos, Bence and Ab, Eiso and Zacarias, Magdalena Ortiz and Theisgen, Stephan and Gruenheit, Nicole and Biskup, Saskia and Schwab, Matthias and Albrecht, Wolfgang and Laufer, Stefan and Nyberg, Scott and Zender, Lars},
  title = {First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {7},
  pages = {1666--1684.e26},
  doi = {10.1016/j.cell.2024.02.023}
}
Kostenlos starten →